This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (110)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Cost-effectiveness of Different Durations of Therapy

Dixie E. Snider, Jr, MD, MPH; Gus J. Caras, MS; Jeffery P. Koplan, MD, MPH

JAMA. 1986;255(12):1579-1583.

Abstract
Daily administration of isoniazid for one year to persons infected with Mycobacterium tuberculosis is effective in considerably reducing the risk of disease. From a practical viewpoint, this approach to prevention is less than ideal because it results in considerable costs as health care providers monitor for possible hepatotoxic effects and because it is difficult to maintain compliance for 12 months. The efficacy and toxicity of isoniazid preventive therapy regimens of 12, 24, and 52 weeks' duration were recently assessed in a study conducted in Eastern Europe. We used data from this study to conduct a cost-effectiveness analysis of the three alternative regimens. The results indicate that over a wide range of assumptions, a regimen of 24 weeks' duration is more cost-effective than either the 12- or 52-week regimen. Using base case estimates, the cost per case prevented for the 24-week regimen was $7,112, compared with $16,024 for the 52-week regimen. Among a cohort of 1,000 persons treated, each additional case prevented by the 52-week regimen would cost $80,807. Thus, a shorter course of isoniazid preventive therapy is relatively cost-effective compared with current policy.

(JAMA 1986;255:1579-1583)

Author Affiliations
From the Division of Tuberculosis Control, Center for Prevention Services (Dr Snider and Mr Caras), and the Office of the Director (Dr Koplan), Centers for Disease Control, Atlanta.

Footnotes
Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement
Mack et al.
Eur Respir J 2009;33:956-973.
ABSTRACT | FULL TEXT  

European framework to decrease the burden of TB/HIV
de Colombani et al.
Eur Respir J 2004;24:493-501.
ABSTRACT | FULL TEXT  

Public Health Impact of Targeted Tuberculosis Screening in Public Schools
Chang et al.
AJPH 2002;92:1942-1945.
FULL TEXT  

Latent tuberculosis infection: old problem, new priorities
Schwartzman
CMAJ 2002;166:759-761.
FULL TEXT  

Management of Tuberculosis in the United States
Small and Fujiwara
NEJM 2001;345:189-200.
FULL TEXT  

Miniature Chest Radiograph Screening for Tuberculosis in Jails . A Cost-effectiveness Analysis
JONES and SCHAFFNER
Am. J. Respir. Crit. Care Med. 2001;164:77-81.
ABSTRACT | FULL TEXT  

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999.
Am. J. Respir. Crit. Care Med. 2000;161:S221-247.
FULL TEXT  

Four-Month, Four-Drug Preventive Therapy for Inactive Pulmonary Tuberculosis
GOLDBERG et al.
Am. J. Respir. Crit. Care Med. 1999;160:508-512.
ABSTRACT | FULL TEXT  

Short-Course Prophylaxis against Tuberculosis in HIV-Infected Persons: A Decision and Cost-Effectiveness Analysis
Rose
ANN INTERN MED 1998;129:779-786.
ABSTRACT | FULL TEXT  

Preventive Therapy for Tuberculosis in HIV-Infected Persons: Analysis of Policy Options Based on Tuberculin Status and CD4+Cell Count
Sawert et al.
Arch Intern Med 1998;158:2112-2121.
ABSTRACT | FULL TEXT  

A Controlled Trial of Isoniazid in Persons with Anergy and Human Immunodeficiency Virus Infection Who Are at High Risk for Tuberculosis
Gordin et al.
NEJM 1997;337:315-320.
ABSTRACT | FULL TEXT  

Long-term Risk of Tuberculosis Among Foreign-born Persons in the United States
Zuber et al.
JAMA 1997;278:304-307.
ABSTRACT  

Antithrombotic Strategy After Total Hip Replacement: A Cost-effectiveness Analysis Comparing Prolonged Oral Anticoagulants With Screening for Deep Vein Thrombosis
Sarasin and Bounameaux
Arch Intern Med 1996;156:1661-1668.
ABSTRACT  

Lesson of the Week: Pitfalls in contact tracing and early diagnosis of childhood tuberculosis
Clark and Cant
BMJ 1996;313:221-222.
FULL TEXT  

Management of an Outbreak of Tuberculosis in a Small Community
Allos et al.
ANN INTERN MED 1996;125:114-117.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Prophylactic Anticoagulation Prolonged After Hospital Discharge Following General Surgery
Sarasin and Bounameaux
Arch Surg 1996;131:694-697.
ABSTRACT  

Isoniazid Prophylaxis: The Importance of Individual Values
Dolan and Bordley
Med Decis Making 1994;14:1-8.
ABSTRACT  

Tuberculosis in the 1990s
Barnes and Barrows
ANN INTERN MED 1993;119:400-410.
ABSTRACT | FULL TEXT  

Isoniazid Chemoprophylaxis
Grzybowski
JAMA 1986;255:1615-1615.
ABSTRACT